Evidence map›Paper›PMID 35089113›Full record

ArticleInnate immunity2022

Delayed inflammation decrease is associated with mortality in Tocilizumab-treated critically ill SARS-CoV-2 patients: A retrospective matched-cohort analysis.

Tomas Urbina, Jean-Rémi Lavillegrand, Marc Garnier, Arsene Mekinian, Jerome Pacanowski, Nathalie Mario, Guillaume Dumas, Geoffroy Hariri, Antoine Pilon, Lucie Darrivère and 9 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Innate immunity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Tomas UrbinaService de Médecine Intensive-Réanimation, 37117Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, France.ORCID 0000-0002-3745-9427
Jean-Rémi LavillegrandService de Médecine Intensive-Réanimation, 37117Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, France.
Marc Garnier27063Sorbonne Université, France.
Arsene Mekinian27063Sorbonne Université, France.
Jerome PacanowskiService de maladies infectieuses, 37117Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, France.
Nathalie MarioDépartement de Biochimie, Hormonologie et Suivi Thérapeutique, 37117Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, France.
Guillaume DumasService de Médecine Intensive-Réanimation, 55663Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, France.
Geoffroy HaririService de Médecine Intensive-Réanimation, 37117Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, France.
Antoine PilonDépartement de Biochimie, Hormonologie et Suivi Thérapeutique, 37117Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, France.
Lucie DarrivèreService d'Anesthésie-Réanimation, 37117Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, France.
Muriel Fartoukh27063Sorbonne Université, France.
Bertrand GuidetService de Médecine Intensive-Réanimation, 37117Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, France.
Eric MauryService de Médecine Intensive-Réanimation, 37117Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, France.
Judith LeblancSorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, France.
Yannick ChantranDépartement d'Immunologie Biologique, 37117Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, France.
Olivier Fain27063Sorbonne Université, France.
Karine Lacombe27063Sorbonne Université, France.
Guillaume Voiriot27063Sorbonne Université, France.
Hafid Ait-OufellaService de Médecine Intensive-Réanimation, 37117Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, France.
Sorbonne Université · FRInserm · FRAssistance Publique – Hôpitaux de Paris · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Little is known about the immuno-inflammatory response to Tocilizumab and its association with outcome in critically-ill SARS-CoV2 pneumonia. In this multicenter retrospective cohort of SARS-CoV-2 patients admitted to three intensive care units between March and April 2020, we matched on gender and SAPS II 21 Tocilizumab-treated patients to 42 non-treated patients. Need for mechanical ventilation was 76% versus 79%. IL-6, C-reactive protein, and fibrinogen had been collected within the first days of admission (T1), 3 d (T2) and 7 d (T3) later. Tocilizumab-treated patients had persistently higher IL-6 plasma levels and persistently lower C-Reactive protein and fibrinogen levels. Among Tocilizumab-treated patients, baseline levels of inflammatory biomarkers were not different according to outcome. Conversely, C-reactive protein and fibrinogen decrease was delayed in non-survivors. C-Reactive protein decreased at T1 in survivors (45 [30-98] vs 170 [69-204] mg/l,

Indexed as

COVID-19 Drug TreatmentAgedAntibodies, Monoclonal, HumanizedAntiviral AgentsBiomarkersCohort StudiesCOVID-19C-Reactive ProteinCritical IllnessFemaleFibrinogenHumansInflammationInterleukin-6MaleMiddle AgedAntibodies, Monoclonal, HumanizedAntiviral AgentsBiomarkersC-Reactive ProteinFibrinogenIL6 protein, humanInterleukin-6tocilizumabC-reactive proteincytokineintensive care unitSARS-CoV-2Tocilizumab

Identifiers

PMID35089113
PMCPMC8841634
OpenAlexW4210390844

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.